United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - erythromycin stearate (unii: lxw024x05m) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythrocin stearate filmtab tablets and other antibacterial drugs, erythrocin stearate filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythrocin stearate tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the e

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - erythromycin stearate (unii: lxw024x05m) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythrocin ® stearate film-coated tablets and other antibacterial drugs, erythrocin ® stearate film-coated tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythrocin ® stearate tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate

United States - English - NLM (National Library of Medicine)

arbor pharmaceuticals, inc. - erythromycin stearate (unii: lxw024x05m) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythrocin® stearate film-coated tablets and other antibacterial drugs, erythrocin® stearate film-coated tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythrocin® stearate tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptibl

United States - English - NLM (National Library of Medicine)

a-s medication solutions - erythromycin stearate (unii: lxw024x05m) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythrocin® stearate film-coated tablets and other antibacterial drugs, erythrocin® stearate film-coated tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythrocin® stearate tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptibl

Australia - English - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - erythromycin lactobionate, quantity: 1.49 g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin panpharma (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment).,? diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers.,? acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythromycin panpharma (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin.,? before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immuno-fluorescence or dark field) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter.,? legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - erythromycin lactobionate, quantity: 1.4882 g/g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin-link (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and s

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - erythromycin stearate (unii: lxw024x05m) (erythromycin - unii:63937kv33d) - erythromycin 250 mg

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - erythromycin stearate (unii: lxw024x05m) (erythromycin - unii:63937kv33d) - erythromycin 500 mg

Canada - English - Health Canada

laboratoires confab inc - erythromycin (erythromycin stearate) - tablet - 250mg - erythromycin (erythromycin stearate) 250mg - erythromycins

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate for oral suspension usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information.) lower-respiratory tract infections of mild to moderate severity caused by streptococcus pneumonia or streptococcus pyogenes . listeriosis caused by listeria monocytogenes . pertussis (whooping cough) caused by bordetella pertussis . erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. respiratory tract infections due to mycoplasma pneumoniae . skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes or staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria: infections due to corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum . intestinal amebiasis caused by entamoeba histolytica (oral erythromycins only). extraenteric amebiasis requires treatment with other agents. acute pelvic inflammatory disease caused by neisseria gonorrhoeae : as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. syphilis caused by treponema pallidum : erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. in treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. erythromycins are indicated for the treatment of the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to chlamydia trachomatis . when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum . legionnaires' disease caused by legionella pneumophila . although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prophylaxis prevention of initial attacks of rheumatic fever penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients.1 the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the american heart association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).1 erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. erythromycin is contraindicated in patients taking terfenadine, astemizole, pimozide, or cisapride. (see precautions - drug interactions .) do not use erythromycin concomitantly with hmg coa reductase inhibitors (statins) that are extensively metabolized by cyp 3a4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.